|Bid||140.65 x 100|
|Ask||144.22 x 100|
|Day's Range||141.82 - 144.46|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||61.94|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.